Spelling suggestions: "subject:"mucosa vaccine""
1 |
Pseudomonas aeruginosa : development of a mucosal vaccine for respiratory infectionThomas, Linda D., n/a January 2001 (has links)
Pseudomonas aeruginosa (P. aeruginosa) is a frequently isolated pathogen that
causes septicaemia and chronic respiratory infection. It exhibits a higher
mortality rate than other gram-negative bacteria and the need for effective
immunotherapy is emphasised by the frequency of antibiotic resistance
associated with this organism. Mucosal immunisation with a whole killed cell P.
aeruginosa vaccine has previously demonstrated a significant immune response
in both rodent studies and human trials. This study is a continuation of that
research, with the major goal being the identification of a purified protein antigen
that could form the basis of a mucosal vaccine against P. aeruginosa.
Specifically, the aims of this study were the development of purification
protocols for the isolation of previously untested protein antigens, assessment of
the efficacy of these antigens to enhance bacterial clearance in an animal model
of acute respiratory infection, determination of the immune parameters that are
associated with the resolution of P. aeruginosa respiratory infection and finally,
cloning of an identified antigen which demonstrated vaccine efficacy.
Protocols were established to isolate proteins for use as antigens in immune
response studies. The proteins purified in this study were Pa 13, Azurin, acyl
carrier protein (ACP), Amidase, Aminopeptidase, KatA and Pa70. These proteins
were used to immunise rats by intestinal intra-Peyer's patch (IPP) inoculation and
intratracheal (IT) boost. The immunisation protocol employed was designed to
target mucosal antigen-specific immune responses where the route of
immunisation, Peyer's patch (PP) intestinal inoculation, is akin to the oral
delivery of antigens to the gut-associated lymphoid tissue (96).
Investigations of a previously uncharacterised antigen, Pa60, later identified this
protein as the P. aeruginosa catalase, KatA. This study demonstrated enhanced
bacterial clearance of both homologous and heterologous challenge following
immunisation with KatA. The level of clearance demonstrated by KatA was
promising when compared to that of killed whole cell immunisation. KatA was
cloned and studies with the recombinant protein showed enhanced bacterial
clearance commensurate with that of the native protein.
Immunisations with other proteins identified four additional antigens which
enhanced bacterial clearance; Pa13, Pa40, Pa45 and Pa70. Amino acid sequence
analysis indicated that Pa13 may be a novel protein, whereas Pa40 was
determined to be amidase and Pa45, aminopeptidase. Pa70 was not successfully
sequenced. These proteins were effective in significantly enhancing bacterial
clearance of homologous P. aeruginosa challenge. For KatA, Pa13 and Pa70,
clearance was associated with a marked phagocytic cell recruitment. In contrast,
amidase and aminopeptidase demonstrated clearance with a minimal cellular
response. Proteins; azurin and ACP were non-protective, failing to clear a live P
aeruginosa challenge. Analysis of the antigen-specific responses of these nonprotective
proteins and comparison with those antigens which enhanced bacterial
clearance were used to determine factors that may contribute to the resolution of
an acute pulmonary infection.
The study has demonstrated that mucosal immunisation using purified protein
antigens can enhance the clearance of pulmonary infection with P. aeruginosa. It
has also contributed to the understanding of immune responses to newfound
antigens of P. aeruginosa and identified antigen-specific responses which
confirm their potential as vaccine candidates.
|
2 |
COMBATING THE HIV/TB CO-INFECTION SYNDEMIC: TESTING A NOVEL RESPIRATORY MUCOSAL ADENOVIRAL TUBERCULOSIS VACCINE IN NAÏVE AND HIV-INFECTED HUMANIZED MICE / TESTING A TB VACCINE IN HUMANIZED MICE IN THE CONTEXT OF HIVChacon, Alexis January 2023 (has links)
HIV and Tuberculosis (TB) co-infection place an immense burden on health care systems as they act in synergy to worsen disease prognoses. TB is the most common cause of death in people living with HIV (PLWH) and in turn, HIV is the most significant risk factor for progressing from latent to active TB disease. While HIV and TB are endemic in sub-Saharan Africa, they also disproportionately affect marginalized populations in Canada. Unfortunately, the only licensed TB vaccine, BCG, does not protect from adult pulmonary TB and is not recommended for PLWH. Thus, the development of novel TB vaccines, which are safe and effective in PLWH, remains an urgent global necessity. We have found that humanized mice (hu-mice) are ideal models to research this as they can be successfully infected with HIV, TB and HIV/TB and recapitulate human disease pathology. A next-generation respiratory mucosal (RM) trivalent chimpanzee adenoviral-vectored vaccine (Tri:ChAd68) was developed and tested in our naïve and HIV-infected hu-mice. When immunizing naïve hu-mice, a trend of increased M.tb-specific CD4+ T cells producing IFNγ and TNFα in the lungs and spleen was observed. After subsequent M.tb infection, the vaccinated naïve hu-mice also exhibited significantly reduced lung mycobacterial burden, tissue dissemination and lung pathology. We then investigated the vaccine immunogenicity and ability to protect from TB in the context of HIV. Our immunized HIV-infected hu-mice were also able to produce M.tb-specific T cells and when challenged with M.tb, we observed a decreased trend in mycobacterial load in the lungs, indicating that the vaccine may be able to offer protection against TB when a prior HIV infection is present. These findings demonstrate the protective potential of the RM Tri:ChAd68 vaccine against TB disease for PLWH. In the future, we will test this vaccine in antiretroviral treated HIV-infected hu-mice to increase clinical significance. / Thesis / Master of Science in Medical Sciences (MSMS) / HIV and TB are major diseases that can occur together, severely worsening patients’ health and challenging global healthcare systems. The current TB vaccine, BCG, isn’t ideal for people living with HIV (PLWH), causing this vulnerable population to be at greater risk of getting TB infection. Therefore, developing a new TB vaccine that is safe and effective in PLWH is an urgent global issue. We used humanized mice that develop human immune cells to test a novel TB vaccine delivered to the lungs (Tri:ChAd68) to see if it could protect against TB and overcome immune challenges from HIV. We saw increased immune responses and lower TB infection in our vaccinated humanized mice and the vaccine appeared to also be beneficial in the mice that had prior HIV infection. This suggests the Tri:ChAd68 vaccine may be able to offer protection against TB in PLWH; however, more studies are needed to conclude this.
|
3 |
Évaluation des pseudo-particules grippales dans un but de vaccination par voies muqueuses / Evaluation of influenza virus-like-particles for mucosal vaccinationPereau Buffin, Sophie 28 June 2019 (has links)
Le virus de la grippe infecte les muqueuses du tractus respiratoire. Un vaccin intranasal induit une réponse immunitaire proche de celle faisant suite à une infection naturelle en bloquant le virus directement sur le site de l'infection et permet une vaccination sans aiguille. Par ailleurs, les vaccins à base de pseudo-particules virales ou Virus-like Particles (VLP) produites sur cellules représentent une alternative intéressante au vaccin classique produit sur oeufs. Les VLP sont des particules non-réplicatives qui ressemblent au virus et qui peuvent être immunogènes même sans adjuvant, en particulier par voie intranasale. Au cours de ma thèse, une plateforme de production de VLP grippales composées d'hémagglutinine, de neuraminidase et de protéine de matrice M1 a été développée par transfection transitoire des cellules de mammifères. Des immunisations de souris BALB/c ont montré que les VLP de type A et B, purifiées et caractérisées, étaient immunogènes à de faibles doses par voie intramusculaire. L'administration par voie intranasale de VLP avec la sous-unité B de la toxine cholérique, comme adjuvant muqueux, a permis d'obtenir des taux d'anticorps sériques comparables à ceux obtenus par immunisation en intramusculaire mais également une forte réponse IgA au niveau des muqueuses. Par ailleurs, le rendement des VLP s'est révélé souche-dépendant et lié aux protéines HA et NA à la surface de la particule. Pour contourner ce problème, un vaccin quadrivalent composé de deux VLP bivalentes exprimant chacune deux HA et NA différentes à la surface a été produit montrant ainsi la flexibilité de cette plateforme / The influenza virus infects the mucous membranes of the respiratory tract. An intranasal vaccine induces an immune response close to the one induced by the natural infection by blocking the virus directly at the site of infection and allows needle-free vaccination. In addition, vaccines based on Virus-like Particles (VLP) produced in cells represent an interesting alternative to the traditional egg-based vaccine. VLPs are non-replicative particles that mimic the virus. Studies on influenza VLPs have shown protection by the intranasal route without adding an adjuvant. During my thesis, a platform for the production of influenza VLPs composed of the hemagglutinin, the neuraminidase and the M1 matrix proteins was developed by transient transfection of mammalian cells. Immunizations of BALB/c mice showed that the purified and characterized type A and B VLPs were immunogenic at low doses by the intramuscular route. The intranasal administration of VLPs with the B subunit of cholera toxin as a mucosal adjuvant resulted in serum antibody levels comparable to those obtained by intramuscular immunization but also a strong IgA response in the mucosal secretions. In addition, VLP yield was found to be strain-dependent and linked to the HA and NA proteins on the surface of the particle. To overcome this problem, a quadrivalent vaccine based on two bivalent VLPs each expressing two different HAs and NAs at the surface was produced, demonstrating the flexibility of this platform
|
4 |
Imunogenicidade e potencial vacinal das flagelinas de Salmonella enterica sorovar Typhimurium. / Immunogenicity and vaccine approach of Salmonella enterica sorovar Typhimurium flagellins.Massis, Liliana Moura 16 October 2007 (has links)
Flagelina, a subunidade estrutural dos flagelos bacterianos, pode ser empregada em estratégias vacinais como carregadora de epitopos antigênicos fusionados ou como adjuvante. Neste trabalho avaliamos a imunogenicidade e o potencial vacinal das flagelinas Salmonella enterica sorovar Typhimurium em camundongos BALB/c após administração pelas vias oral ou intraperitoneal. Os resultados indicam que animais imunizados pela via oral com linhagens flageladas de S. Typhimurium não desenvolvem respostas de anticorpos, sistêmicos ou secretados, anti-flagelina, por outro lado, ativam respostas celulares específicas para as flagelinas em função da via de administração utilizada. Observamos ainda que as diferentes flagelinas testadas apresentam efeito adjuvante quando co-administradas pela via nasal com a fímbria CFA/I de ETEC. Em suma, os resultados apresentados contribuem para um melhor conhecimento sobre as propriedades imunológicas e adjuvantes das flagelinas de S. Typhimurium e agregam informações para o uso racional dessas proteínas em formulações vacinais. / Flagellin, the structural subunit of bacterial flagella, can be used in vaccine development as a fused antigenic epitope carrier or as an adjuvant. In this work we evaluated the immunogenicity and vaccine approach of S. Typhimurium flagellin in BALB/c mice after administration by oral or intraperitoneal route. Our results indicate that mice immunized by oral route with flagellated S. Typhimurium strains do not develop any anti-flagellin antibody response, be it serum or secreted. On the other hand, specific anti-flagellin cellular response was observed depending on the chosen route of immunization with S. Typhimurium attenuated strain. Furthermore, all flagellins tested proved to be efficient adjuvants when co-administrated with CFA/I fimbriae by nasal route. Together, these results contribute to a better understanding of the immunological and adjuvant properties of S. Typhimurium flagellins and also provide information on the rational use of these proteins in vaccine development.
|
5 |
Imunogenicidade e potencial vacinal das flagelinas de Salmonella enterica sorovar Typhimurium. / Immunogenicity and vaccine approach of Salmonella enterica sorovar Typhimurium flagellins.Liliana Moura Massis 16 October 2007 (has links)
Flagelina, a subunidade estrutural dos flagelos bacterianos, pode ser empregada em estratégias vacinais como carregadora de epitopos antigênicos fusionados ou como adjuvante. Neste trabalho avaliamos a imunogenicidade e o potencial vacinal das flagelinas Salmonella enterica sorovar Typhimurium em camundongos BALB/c após administração pelas vias oral ou intraperitoneal. Os resultados indicam que animais imunizados pela via oral com linhagens flageladas de S. Typhimurium não desenvolvem respostas de anticorpos, sistêmicos ou secretados, anti-flagelina, por outro lado, ativam respostas celulares específicas para as flagelinas em função da via de administração utilizada. Observamos ainda que as diferentes flagelinas testadas apresentam efeito adjuvante quando co-administradas pela via nasal com a fímbria CFA/I de ETEC. Em suma, os resultados apresentados contribuem para um melhor conhecimento sobre as propriedades imunológicas e adjuvantes das flagelinas de S. Typhimurium e agregam informações para o uso racional dessas proteínas em formulações vacinais. / Flagellin, the structural subunit of bacterial flagella, can be used in vaccine development as a fused antigenic epitope carrier or as an adjuvant. In this work we evaluated the immunogenicity and vaccine approach of S. Typhimurium flagellin in BALB/c mice after administration by oral or intraperitoneal route. Our results indicate that mice immunized by oral route with flagellated S. Typhimurium strains do not develop any anti-flagellin antibody response, be it serum or secreted. On the other hand, specific anti-flagellin cellular response was observed depending on the chosen route of immunization with S. Typhimurium attenuated strain. Furthermore, all flagellins tested proved to be efficient adjuvants when co-administrated with CFA/I fimbriae by nasal route. Together, these results contribute to a better understanding of the immunological and adjuvant properties of S. Typhimurium flagellins and also provide information on the rational use of these proteins in vaccine development.
|
Page generated in 0.0354 seconds